辛三醇 | 112196-85-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 辛三醇
• 英文名称: 1,2,3-octanetriol
• 英文别名: octane-1,2,3-triol
• CAS: 112196-85-7
• 化学式: C₈H₁₈O₃
• 分子量: 162.229
• InChiKey: QSQGNBGEHSFMAA-UHFFFAOYSA-N

物化性质

• 沸点：
  319.2±22.0 °C(Predicted)
• 密度：
  1.054±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  辛三醇 在 二甲基二环氧乙烷 作用下， 以 丙酮 为溶剂， 反应 24.0h， 以66%的产率得到1,2-dihydroxyoctan-3-one
  参考文献：
  名称：

  Regioselective oxidation of azidodiols, bromodiols and triol derivatives by dimethyldioxirane

  摘要：

  Azidodiols, bromodiols and triol derivatives were regioselectively monooxidised to the corresponding ketols using dimethyldioxirane. This regioselectivity is essentially determined by dipolar functionalities close to the potential reactive carbinol. These results make the reactivity of polyols with dimethyldioxirane highly predictable. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(98)00885-0

文献信息

• [EN] METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE<br/>[FR] ANALOGUES ROBUSTES SUR LE PLAN MÉTABOLIQUE DES CYP-EICOSANOÏDES POUR LE TRAITEMENT DES MALADIES CARDIAQUES
  申请人：OMEICOS THERAPEUTICS GMBH

  公开号：WO2017013265A1

  公开（公告）日：2017-01-26

  The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of cardiovascular diseases.

  本发明涉及符合一般式（I）的化合物，这些化合物是从ω-3多不饱和脂肪酸（n-3 PUFAs）衍生的生物活性脂质介质的代谢稳健类似物。本发明还涉及含有这些化合物中的一个或多个的组合物，以及利用这些化合物或组合物治疗或预防心血管疾病。
• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products
  申请人：——

  公开号：US20030228259A1

  公开（公告）日：2003-12-11

  Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in accessible biological samples are disclosed herein.

  本发明公开了确定生物分子生物合成或分解速率的方法，具体为通过取样可获取的生物样本中的代谢衍生物和分解产物，测量难以或不易直接取样的生物分子的生物合成和分解速率。
• Modified Human Apolipoprotein A-1 and Their Uses
  申请人：Knudsen Nick

  公开号：US20110178029A1

  公开（公告）日：2011-07-21

  Modified human apolipoprotein A-I polypeptides and uses thereof are provided.

  提供了改良的人类载脂蛋白A-I多肽及其用途。
• [EN] ANTIBACTERIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIBACTÉRIENS
  申请人：UNIV SYDNEY

  公开号：WO2014153624A1

  公开（公告）日：2014-10-02

  The invention relates to antibacterial compounds, methods for synthesis and use thereof in antibacterial applications.

  这项发明涉及抗菌化合物，其合成方法以及在抗菌应用中的使用。